Patents by Inventor Fred Hassan

Fred Hassan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10960075
    Abstract: A composition includes an oral thin film pharmaceutical dosage form configured to disintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva. The dosage can completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: March 30, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Patent number: 10888522
    Abstract: Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: January 12, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan, Christopher Diorio, Fred Hassan
  • Publication number: 20200268886
    Abstract: A composition includes a pharmaceutical tablet dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Application
    Filed: May 13, 2020
    Publication date: August 27, 2020
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Publication number: 20200268887
    Abstract: A composition includes a pharmaceutical dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Application
    Filed: May 13, 2020
    Publication date: August 27, 2020
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Publication number: 20200163886
    Abstract: Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.
    Type: Application
    Filed: December 3, 2018
    Publication date: May 28, 2020
    Inventors: Syed M. Shah, Daniel Hassan, Christopher Diorio, Fred Hassan
  • Publication number: 20200069803
    Abstract: A composition includes an oral thin film pharmaceutical dosage form configured to disintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva. The dosage can completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Application
    Filed: November 6, 2019
    Publication date: March 5, 2020
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Patent number: 10500280
    Abstract: A composition includes a pharmaceutical dosage form configured to dinsintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva. The amount of disintegrant is sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: December 10, 2019
    Assignee: Physician's Seal, LLC
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Publication number: 20190328881
    Abstract: A valerian composition includes a therapeutically effective pharmaceutical dosage form having a solid core including a polymer in which valerian and a valerian stability improving amount of an acidifying agent are contained. The valerian stability improving amount of acidifying agent being sufficient to impart a pH of 2 to 5 to the polymer.
    Type: Application
    Filed: July 9, 2019
    Publication date: October 31, 2019
    Inventors: Syed M. Shah, Christopher Diorio, Daniel Hassan, Fred Hassan
  • Publication number: 20190321475
    Abstract: A valerian composition includes a therapeutically effective pharmaceutical dosage form having a solid core including a polymer in which valerian and a valerian stability improving amount of an acidifying agent are contained. The valerian stability improving amount of acidifying agent being sufficient to impart a pH of 2 to 5 to the polymer.
    Type: Application
    Filed: July 3, 2019
    Publication date: October 24, 2019
    Inventors: Syed M. Shah, Christopher Diorio, Daniel Hassan, Fred Hassan
  • Publication number: 20190307701
    Abstract: A method of making an L-menthol dosage form includes forming a wet granulation including an L-menthol source and at least one pharmaceutical excipient. The wet granulation is extruded into an extrudate and the extrudate is cut into individual core pieces. The individual core pieces are spheronized into individual spheronized cores and the individual spheronized cores are dried to form dried individual spheronized cores. The dried individual spheronized cores are spray coated with a liquid proteinaceous material that forms a film of a proteinaceous material over the dried individual spheronized cores. The film of proteinaceous material is dried over the dried individual spheronized cores to form individual subcoated cores. An enteric coating is applied and dried over the individual subcoated cores to form a plurality of individual enteric coated cores.
    Type: Application
    Filed: June 21, 2019
    Publication date: October 10, 2019
    Inventors: Syed M. Shah, Fred Hassan
  • Patent number: 10420730
    Abstract: A storage stable L-menthol composition including a tablet, caplet, capsule, or sachet dosage form has therein a core containing crystalline L-menthol and at least one pharmaceutical excipient. A proteinaceous coating of a continuous film of proteinaceous material is over the core. The film is effective to substantially prevent the crystalline L-menthol from volatilizing and leaving the core when stored at a temperature of 40 degrees C. and 75% relative humidity from between 1 day to 30 days. The dosage form contains an effective amount of the crystalline L-menthol for treating a gastrointestinal disorder.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: September 24, 2019
    Assignee: Zx Pharma, LLC
    Inventors: Syed M. Shah, Fred Hassan
  • Patent number: 10342873
    Abstract: A valerian composition includes a therapeutically effective pharmaceutical dosage form having a solid core including a polymer in which valerian and a valerian stability improving amount of an acidifying agent are contained. The valerian stability improving amount of acidifying agent being sufficient to impart a pH of 2 to 5 to the polymer.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: July 9, 2019
    Assignee: Physician's Seal, LLC
    Inventors: Syed M. Shah, Christopher Diorio, Daniel Hassan, Fred Hassan
  • Publication number: 20190031417
    Abstract: Melatonin tablets with a high concentration of citric acid are packaged in a blister package that enhances storage stability. Such a packaging material includes a blister film forming a cavity holding the tablet therein. The blister film includes a polyvinyl chloride (PVC) film having a thickness of 180 ?m to 270 ?m coated with a polyvinylidene chloride (PVDC) coating having a coating weight of 110 g/m2 to 130 g/m2. An aluminum foil lid closes the cavity and encapsulates the tablet within the blister film and lid. The lid has a thickness of 20 ?m to 30 ?m.
    Type: Application
    Filed: July 26, 2018
    Publication date: January 31, 2019
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan
  • Publication number: 20180360967
    Abstract: A composition includes a pharmaceutical dosage form configured to dinsintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva. The amount of disintegrant is sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Application
    Filed: June 15, 2018
    Publication date: December 20, 2018
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Patent number: 10143654
    Abstract: Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: December 4, 2018
    Assignee: Physician's Seal, LLC
    Inventors: Syed M. Shah, Daniel Hassan, Christopher Diorio, Fred Hassan
  • Publication number: 20170319697
    Abstract: A valerian composition includes a therapeutically effective pharmaceutical dosage form having a solid core including a polymer in which valerian and a valerian stability improving amount of an acidifying agent are contained. The valerian stability improving amount of acidifying agent being sufficient to impart a pH of 2 to 5 to the polymer.
    Type: Application
    Filed: May 4, 2017
    Publication date: November 9, 2017
    Applicant: Physician's Seal, LLC
    Inventors: Syed M. Shah, Christopher Diorio, Daniel Hassan, Fred Hassan
  • Publication number: 20170319476
    Abstract: A composition includes a therapeutically effective oral pharmaceutical dosage form that becomes buoyant upon contact with gastric fluid. The dosage form includes an active ingredient combination including an amino acid source and a zinc source, an anionic polymer, an effervescent agent, and a pH buffer. The dosage form is effective for releasing the active ingredient combination while buoyant on gastric fluid.
    Type: Application
    Filed: May 4, 2017
    Publication date: November 9, 2017
    Applicant: Physician's Seal, LLC
    Inventors: Daniel Hassan, Syed M. Shah, Fred Hassan, Christopher Diorio
  • Publication number: 20170266125
    Abstract: A pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core including crystalline L-menthol dissolved in a terpene-based essential oil. A proteinaceous coating of a continuous film of proteinaceous material is over the core.
    Type: Application
    Filed: June 6, 2017
    Publication date: September 21, 2017
    Inventors: Syed M. Shah, Fred Hassan, Daniel Hassan, Sarah Hassan
  • Publication number: 20170231940
    Abstract: A composition includes a therapeutically effective pharmaceutical dosage form including a plurality of individual particulates. The individual particulates respectively have: a core including an active ingredient combination of an L-carnitine and a nootropic substance and a release controlling polymer over the core that substantially prevents release of the active ingredients in stomach acid and permits release of the active ingredients in an intestinal pH environment. The composition may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body and/or cognitive impairment.
    Type: Application
    Filed: May 4, 2017
    Publication date: August 17, 2017
    Applicant: Physician's Seal, LLC
    Inventors: Syed M. Shah, Noreen Hassan, Christopher Diorio, Fred Hassan
  • Patent number: D907760
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: January 12, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Daniel Hassan, Fred Hassan